Literature DB >> 3518022

Microbial ribosomal vaccines.

R L Gregory.   

Abstract

Ribosomal vaccines have been prepared from several different bacterial, fungal, and protozoan microorganisms. Most of these preparations offer a higher degree of protection than do vaccines made from the homologous whole cells, but the mode of protection is controversial. All of the reported ribosomal vaccines are contaminated with cell surface determinants. Antisera raised to ribosomal preparations are directed to innate ribosomal components as well as to surface antigens. Several hypotheses exist for the reported protection from disease: the cell surface contaminants serve as the protective moieties; ribosomes act as potent adjuvants for contaminating cell surface determinants; ribosomes innately contain antigenic determinants that cross-react with cell surface antigens; recently translated cell surface polypeptides are still attached to the ribosomal RNA in the ribosomes; ribosomes migrate from the cytoplasm of the microbe to the periphery of the cell, and ribosomal antigens are exposed on the cell surface; or ribosomes contain messenger RNA and produce microbial cell surface polypeptides in immunized individuals. A short description of the biochemical, biophysical, and structural characteristics of prokaryotic and eukaryotic ribosomes is presented, followed by a discussion of the ability of various ribosomal vaccines to protect against infectious agents.

Mesh:

Substances:

Year:  1986        PMID: 3518022     DOI: 10.1093/clinids/8.2.208

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  17 in total

Review 1.  Ribosomal immunotherapy for recurrent respiratory tract infections in children.

Authors:  Marie C Béné; Gilbert C Faure
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 2.  Fungal ribosomal vaccines. I. Histoplasma and Candida vaccines.

Authors:  E Segal
Journal:  Mycopathologia       Date:  1989-01       Impact factor: 2.574

Review 3.  Pharmacology of ribosomal immunotherapy.

Authors:  J Clot
Journal:  Drugs       Date:  1997       Impact factor: 9.546

4.  From Peyer's patches to tonsils. Specific stimulation with ribosomal immunotherapy.

Authors:  M C Béné; G C Faure
Journal:  Drugs       Date:  1997       Impact factor: 9.546

5.  Mycobacterium tuberculosis Rv0652 stimulates production of tumour necrosis factor and monocytes chemoattractant protein-1 in macrophages through the Toll-like receptor 4 pathway.

Authors:  Kwangwook Kim; Hosung Sohn; Jong-Seok Kim; Han-Gyu Choi; Eui-Hong Byun; Kang-In Lee; Sung Jae Shin; Chang-Hwa Song; Jeong-Kyu Park; Hwa-Jung Kim
Journal:  Immunology       Date:  2012-06       Impact factor: 7.397

6.  Fungal ribosomal vaccines. II. Dermatophyte vaccine--initial studies on the antigenicity of a crude ribosomal fraction from Microsporum canis.

Authors:  D Elad; E Segal
Journal:  Mycopathologia       Date:  1989-01       Impact factor: 2.574

7.  Immunological properties of ribosomal proteins from Mycobacterium bovis BCG.

Authors:  S Tantimavanich; S Nagai; H Nomaguchi; M Kinomoto; N Ohara; T Yamada
Journal:  Infect Immun       Date:  1993-09       Impact factor: 3.441

8.  Recombinant L7/L12 ribosomal protein and gamma-irradiated Brucella abortus induce a T-helper 1 subset response from murine CD4+ T cells.

Authors:  S C Oliveira; Y Zhu; G A Splitter
Journal:  Immunology       Date:  1994-12       Impact factor: 7.397

9.  Brucella ribosomal protein L7/L12 is a major component in the antigenicity of brucellin INRA for delayed-type hypersensitivity in brucella-sensitized guinea pigs.

Authors:  G Bachrach; M Banai; S Bardenstein; G Hoida; A Genizi; H Bercovier
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

10.  Characterization of immune response to oral administration of Streptococcus sobrinus ribosomal preparations in liposomes.

Authors:  R L Gregory; S M Michalek; G Richardson; C Harmon; T Hilton; J R McGhee
Journal:  Infect Immun       Date:  1986-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.